Pieris Pharmaceuticals Inc (PIRS) Receives Average Recommendation of “Hold” from Analysts

Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) have been assigned an average rating of “Hold” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $6.00.

A number of brokerages have recently issued reports on PIRS. Zacks Investment Research raised Pieris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a report on Friday, April 19th. ValuEngine raised Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 24th. Finally, HC Wainwright set a $7.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 23rd.

Shares of NASDAQ PIRS traded up $0.04 during trading hours on Friday, hitting $4.14. 4,737 shares of the company’s stock were exchanged, compared to its average volume of 606,865. Pieris Pharmaceuticals has a 1-year low of $2.39 and a 1-year high of $6.55. The stock has a market capitalization of $205.94 million, a PE ratio of -8.30 and a beta of 1.22.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.05). The business had revenue of $4.91 million for the quarter, compared to analyst estimates of $6.92 million. Pieris Pharmaceuticals had a negative return on equity of 64.64% and a negative net margin of 84.75%. As a group, sell-side analysts predict that Pieris Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA bought a new stake in Pieris Pharmaceuticals during the 1st quarter worth approximately $36,000. SG Americas Securities LLC bought a new position in Pieris Pharmaceuticals in the 4th quarter valued at $36,000. Prudential Financial Inc. bought a new position in Pieris Pharmaceuticals in the 4th quarter valued at $43,000. Parametric Portfolio Associates LLC bought a new position in Pieris Pharmaceuticals in the 1st quarter valued at $57,000. Finally, Alambic Investment Management L.P. bought a new position in Pieris Pharmaceuticals in the 4th quarter valued at $59,000. 59.70% of the stock is owned by institutional investors and hedge funds.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

See Also: Beige Book

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.